Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Association between aspirin use and lung cancer incidence depends on high-frequency use, bodyweight, and age in U.S. adults.

About this Publication
Title
Association between aspirin use and lung cancer incidence depends on high-frequency use, bodyweight, and age in U.S. adults.
Pubmed ID
33569321 (View this publication on the PubMed website)
Digital Object Identifier
Publication
Transl Lung Cancer Res. 2021 Jan; Volume 10 (Issue 1): Pages 392-401
Authors
Dong X, He J, Lin L, Zhu Y, Chen C, Su L, Zhao Y, Zhang R, Wei Y, Chen F, Christiani DC
Affiliations
  • Department of Biostatistics, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
  • Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Abstract

BACKGROUND: Chemoprevention of cancer with aspirin is controversial as a primary prevention strategy. We sought to investigate the association between aspirin frequency and risk of lung cancer in The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

METHODS: Using data from 101,722 participants in PLCO, we used a Cox regression model coupling with propensity score to detect the association between aspirin frequency and lung cancer risk.

RESULTS: High-frequency aspirin use significantly increased risk of lung cancer by 28% compared to no use (HR =1.28; 95% CI, 1.14-1.45; P=3.37×10-5), especially for current smoker (HR =1.30; 95% CI, 1.07-1.57; P=6.82×10-3). However, the increased lung cancer risk due to high-frequency aspirin use significantly decreased with increasing bodyweight (HRinteraction =0.96; 95% CI, 0.94-0.99; P=1.26×10-2). Further, for participants with bodyweight <80 kg, high-frequency aspirin use showed an elevated risk at <76 years of age (HRage<76 =1.47; 95% CI, 1.25-1.73; P=3.81×10-6). Our study used propensity score under various confounding and stratification analyses by cardio-cerebrovascular status, which all presented similar evidences.

CONCLUSIONS: High-frequency aspirin use is associated with the increased risk of lung cancer. Current smoker or people with age <76 years and bodyweight <80 kg should be more cautious to high-frequency aspirin use for lung cancer chemoprevention. This study provides a new insight for lung cancer chemoprevention.

Related CDAS Studies